Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02367 巨子生物
Listing Date2022/11/04
Listing Price24.300
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    1 lot
  • One Lot Success Rate

Giant Biogene Holding Co., Ltd is a leader in the bioactive ingredient-based professional skin treatment product industry in China. It designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient.

The Group’s market share was approximately 1.1 % of China’s overall skin care and treatment market in terms of retail sales in 2021. It was the second-largest professional skin treatment product company in China in 2021. It is the first company to obtain a medical device registration for recombinant collagen-based product in China. Collgene (可麗金) and Comfy (可復美), its flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively.

The Group’s product pipeline included 102 product candidates, comprising 49 functional skincare products, 37 medical dressings and four skin rejuvenation products under its beauty product portfolio, as well as two biomedical products, seven functional foods and three food products for special medical purposes under our health product portfolio.

The Group implements dual-pronged “medical institution mass consumer” sales strategy targeting both medical institutions and mass market. It had sold and distributed products to over 1,000 public hospitals, approximately 1,700 private hospitals and clinics, as well as approximately 300 pharmacy chain brands across China. In addition, it have also built a nationwide mass market sales network through direct sales and distributors.

MarketHong Kong (Main Board)
Business NatureHousehold & Personal Products
Major Business AreaChina
Board Lot200
No. of Offer Shares22.61M shares
No. of International Offer Shares20.35M shares
No. of HK Offer Shares2.26M shares
Offer Price$24.30 - $27.70
Stock Code2367
Sponsor(s)Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited, GF Securities (Hong Kong) Brokerage Limited, Futu Securities International (Hong Kong) Limited, Silverbricks Securities Company Limited
Application PeriodOct 25 (Tue) - noon, Oct 28 (Fri)
Price Determination DateOct 28 (Fri)
Result Announcement DateOn or before Nov 03 (Thu)
Result Announcement DateOn or before Nov 03 (Thu)
Dealings in Shares commence onNov 04, 2022. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$24.30 - $27.70
Capitalization24.10B - 27.47B
NAV / share ($)$2.25 - $2.33 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 26.00, the net proceeds raised would be HKD 532.10M, of which
11% : Investment in R&D to enlarge R&D team, expand R&D facilities and conduct testing
28% : Expansion of manufacturing capacity with respect to product portfolios and bioactive ingredients
46% : Enhance omni-channel sales and distribution network to enhance brand recognition
5% : Enhancement of operation and information systems
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.